Download PDF
Planta Med 2009; 75(11): 1227-1230
DOI: 10.1055/s-0029-1185533
Pharmacology
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Antitumor Activity of Resveratrol and its Sulfated Metabolites against Human Breast Cancer Cells

Michaela Miksits1 , Katrin Wlcek1 , Martin Svoboda2 , Olaf Kunert3 , Ernst Haslinger3 , Theresia Thalhammer2 , Thomas Szekeres4 , Walter Jäger1
  • 1Department of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria
  • 2Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
  • 3Department of Pharmaceutical Chemistry, University of Graz, Graz, Austria
  • 4Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria
Further Information

Publication History

received Sept. 19, 2008 revised January 23, 2009

accepted February 28, 2009

Publication Date:
06 April 2009 (online)

Also available at
    Permissions and Reprints

Abstract

Resveratrol (3,4′,5-trihydroxy-trans-stilbene) is a naturally occurring polyphenolic compound found in grapes, wine and medicinal plants with a variety of biological and pharmacological activities including pronounced anticancer properties. These effects are observed despite its extremely low bioavailability and rapid clearance from the circulation due to extensive sulfation and glucuronidation in the intestine and liver. In order to determine whether its metabolites demonstrate any cytotoxic properties, three major human sulfated conjugates of resveratrol were synthesized and their anticancer activity evaluated against three breast cancer cell lines (two hormone-dependent: MCF-7 and ZR-75-1; one hormone-independent: MDA‐MB‐231) and one immortalized breast epithelial cell line (MCF-10A). We found that, in contrast to resveratrol, all three sulfated metabolites were less potent against MCF-7, MDA‐MB‐231 and ZR-75-1 cells (trans-resveratrol 3-O-sulfate < trans-resveratrol 4′-O-sulfate < trans-resveratrol 3-O-4′-O-disulfate) indicating that any conjugation of the phenolic groups with sulfuric acid strongly affecting the cytotoxicity. Interestingly, all sulfated metabolites were reduced about 10-fold, but showed nearly equal cytotoxicity towards nonmalignant MCF-10A breast cells (IC50 s: 202–228 µM). In summary, in contrast to resveratrol its sulfated metabolites showed poor cytotoxicity in human malignant and nonmalignant breast cancer cell lines. However, the in vitro activity of the metabolites may not necessarily reflect their in vivo function, given the fact that the ubiquitously existing human sulfatases could convert the metabolites back to resveratrol in humans.

Key words

resveratrol - 3,4′,5‐trihydroxy‐trans‐stilbene - metabolites - cytotoxicity - cancer cell lines

References

  • 1 Burns J, Yokota T, Ashihara H, Lean M E, Crozier A. Plant foods and herbal sources of resveratrol.  J Agric Food Chem. 2002;  50 3337-3340
    CrossrefPubMedSearch in Google Scholar
  • 2 Vastano B C, Chen Y, Zhu N, Ho C T, Zhou Z, Rosen R T. Isolation and identification of stilbenes in two varieties of Polygonum cuspidatum.  J Agric Food Chem. 2000;  48 253-256
    CrossrefPubMedSearch in Google Scholar
  • 3 Frémont L, Belguendouz L, Delpal S. Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids.  Life Sci. 1999;  64 2511-2521
    CrossrefPubMedSearch in Google Scholar
  • 4 Zou J G, Huang Y Z, Chen Q, Wei E H, Hsieh T C, Wu J M. Resveratrol inhibits copper ioninduced and azo compound-initiated oxidative modification of human low density lipoprotein.  Biochem Mol Biol Int. 1999;  47 1089-1096
    PubMedSearch in Google Scholar
  • 5 Murias M, Handler N, Erker T, Pleban K, Ecker G, Saiko P, Szekeres T, Jäger W. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship.  Bioorg Med Chem. 2004;  12 5571-5578
    CrossrefPubMedSearch in Google Scholar
  • 6 Murias M, Jäger W, Handler N, Erker T, Horvath Z, Szekeres T, Nohl H, Gille L. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship.  Biochem Pharmacol. 2005;  69 903-912
    CrossrefPubMedSearch in Google Scholar
  • 7 Jang M, Cai L, Udeani G O, Slowing K V, Thomas C F, Beecher C W, Fong H H, Famsworth N R, Kinghorn A D, Mehta R G, Moon R C, Pezzuto J M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.  Science. 1997;  275 218-220
    CrossrefPubMedSearch in Google Scholar
  • 8 Ragione F D, Cucciola V, Borriello A, Pietra V D, Racioppi L, Soldati G, Manna C, Galleti P, Zappia V. Resveratrol arrests the cell division cycle at S/G2 phase transition.  Biochem Biophys Res Commun. 1998;  250 53-58
    CrossrefPubMedSearch in Google Scholar
  • 9 Saiko P, Pemberger M, Horvath Z, Savinc I, Grusch M, Handler N, Erker T, Jaeger W, Fritzer-Szekeres M, Szekeres T. Novel resveratrol analogs induce apoptosis and cause cell cycle arrest in HT29 human colon cancer cells: inhibition of ribonucleotide reductase activity.  Oncol Rep. 2008;  19 1621-1626
    PubMedSearch in Google Scholar
  • 10 Levi F, Pasche C, Lucchini F, Guidoni R, Ferrarono M, La V C. Resveratrol and breast cancer risk.  Eur J Cancer Prev. 2005;  14 139-142
    CrossrefPubMedSearch in Google Scholar
  • 11 Walle T, Hsieh F, DeLegge M H, Oatis Jr J E, Walle U K. High absorption but very low bioavailability of oral resveratrol in humans.  Drug Metab Dispos. 2004;  32 1377-1382
    CrossrefPubMedSearch in Google Scholar
  • 12 Burkon A, Somoza V. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides – two novel resveratrol metabolites in human plasma.  Mol Nutr Food Res. 2008;  52 549-557
    CrossrefPubMedSearch in Google Scholar
  • 13 Marier J F, Vachon P, Gritsas A, Zhang J, Moreau J P, Ducharme M P. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model.  J Pharmacol Exp Ther. 2002;  302 369-373
    CrossrefPubMedSearch in Google Scholar
  • 14 Maier-Salamon A, Hagenauer B, Wirth M, Gabor F, Szekeres T, Jäger W. Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites.  Pharm Res. 2006;  23 2107-2115
    CrossrefPubMedSearch in Google Scholar
  • 15 Miksits M, Maier-Salamon A, Aust S, Thalhammer T, Reznicek G, Kunert O, Haslinger E, Szekeres T, Jaeger W. Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1.  Xenobiotica. 2005;  35 1101-1119
    CrossrefPubMedSearch in Google Scholar
  • 16 Murias M, Miksits M, Aust S, Spatzenegger M, Thalhammer T, Szekeres T, Jaeger W. Metabolism of resveratrol in breast cancer cell lines: impact of sulfotransferase 1A1 expression on cell growth inhibition.  Cancer Lett. 2008;  261 172-182
    CrossrefPubMedSearch in Google Scholar
  • 17 Kawai N, Fujibayashi Y, Kuwabara S, Takao K, Ijuin Y, Kobayashi S. Synthesis of a potential key intermediate of akaterpin, specific inhibitor of PI‐PLC.  Tetrahedron. 2000;  56 6467-6478
    CrossrefPubMedSearch in Google Scholar
  • 18 Yu C, Shin Y G, Chow A, Li Y, Kosmeder J W, Lee Y S, Hirschelman W H, Pezzuto J M, Mehta R G, van Breemen R B. Human, rat, and mouse metabolism of resveratrol.  Pharm Res. 2002;  19 1907-1914
    CrossrefPubMedSearch in Google Scholar
  • 19 Wenzel E, Soldo T, Erbersdobler H, Somoza V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats.  Mol Nutr Food Res. 2005;  49 482-494
    CrossrefPubMedSearch in Google Scholar
  • 20 Worland P J, Kaur G, Stetler-Stevenson M, Sebers S, Sartor O, Sausville E A. Alteration of the phosphorylation state of p 34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity.  Biochem Pharmacol. 1993;  46 1831-1840
    CrossrefPubMedSearch in Google Scholar
  • 21 Carlson B A, Dubay M M, Sausville E A, Brizuela L, Worland P J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.  Cancer Res. 1996;  56 2973-2978
    PubMedSearch in Google Scholar
  • 22 Wang L X, Heredia A, Song H, Zhang Z, Yu B, Davis C, Redfield R. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity.  J Pharm Sci. 2004;  93 2448-2457
    CrossrefPubMedSearch in Google Scholar
  • 23 Pasqualini J R, Chetrite G S. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.  J Steroid Biochem Mol Biol. 2005;  93 221-236
    CrossrefPubMedSearch in Google Scholar
  • 24 Ghosh D. Human sulfatases: a structural perspective to catalysis.  Cell Mol Life Sci. 2007;  64 2013-2022
    CrossrefPubMedSearch in Google Scholar
  • 25 Utsumi T, Yoshimura N, Takeuchi S, Maruta M, Maeda K, Harada N. Elevated steroid sulfatase expression in breast cancers.  J Steroid Biochem Mol Biol. 2000;  73 141-145
    CrossrefPubMedSearch in Google Scholar

Dr. Walter Jäger

Department of Clinical Pharmacy and Diagnostics
University of Vienna

Althanstrasse 14

1090 Vienna

Austria

Phone: + 43 14 27 75 55 76

Fax: + 43 1 42 77 95 55

Email: walter.jaeger@univie.ac.at